Latest Research And Development News

BluGlass has agreed an A$8.0 million R&D-backed loan with Rockford, refinancing its existing Radium facility and adding about A$5.5 million of liquidity. The funding gives the laser developer more room to scale, but carries a 16.5% interest rate and repayment obligations tied to future tax refunds.

PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.

Orbit Resources enters FY2027 with a 17.52Mt Lewis Ponds resource, a preliminary study pointing to a A$481 million pre-tax NPV and a new polymetallic sulphide discovery outside the existing resource. The gains come with familiar junior-miner constraints: a A$3.49 million annual loss, A$3.69 million in cash and further funding still required.

Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.

Latrobe Magnesium has secured A$8.5 million in equity funding to complete its Latrobe Valley demonstration plant and advance a proposed South Carolina magnesium project. The raising gives the company near-term funding certainty, but also brings further dilution and leaves the larger US development dependent on future capital.

AML3D will contribute about A$530,000 to a three-year, A$3.89 million research project aimed at qualifying its Wire-Arc Additive Manufacturing technology for aerospace tooling. The project carries no immediate revenue, but could open the door to future production contracts if qualification succeeds.

Gold Hydrogen has advanced Ramsay drilling, testing and commercial studies, but its annual report carries a material uncertainty over the company’s ability to continue as a going concern. The pre-revenue explorer ended FY2026 with $9.42 million in cash after spending heavily on exploration.

Nyrada has secured AU$12.0 million from institutional and sophisticated investors, with a further AU$2.0 million shareholder purchase plan planned, giving the biotech funding to advance its Xolatryp clinical programs. The raise also carries substantial dilution and an unusually large proposed director subscription worth AU$5.125 million, subject to shareholder approval.

Vectus Biosystems swung to a $1.56 million FY2026 profit, but the result was driven largely by the sale of its VB4-P5 compound for XORTX shares and warrants rather than recurring operations. The company is now directing its resources towards VB0004 while its auditor flags material uncertainty over ongoing funding.

CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.

Austco Healthcare delivered record FY26 revenue and statutory profit, with stronger margins, cash generation and a modest recovery in contracted orders entering the new financial year. The company is pairing that momentum with further reseller consolidation, including the $2.88 million acquisition of Medical Communications Systems.

Hydrix has secured a three-year contract with Singapore’s National Heart Centre to deploy the Implicity remote cardiac monitoring platform. The agreement is expected to generate about A$0.625 million, although the final value depends on patient volumes and implementation.